Edap Tms (FOCL) Stock Price, Financials & Analysis

Key Stats

Market Cap155.74 Mn

P/E-4.01

P/S2.26

Total Debt (Qtr)39.91 Mn

Revenue Growth (1y) (Qtr)38.85

Add ratio to table…

About

EDAP TMS S. A. is a medical technology company focused on the development, manufacturing, marketing, and sale of noninvasive therapeutic ultrasound and energy based medical devices. The company's core technology is high intensity focused ultrasound (HIFU) embodied in its flagship product, the Focal One Robotic HIFU system, which is used primarily in urology for the treatment of prostate cancer and is being expanded to address benign prostatic hyperplasia and endometriosis. EDAP TMS S. A. manufactures and sells its products globally, with headquarters in Vaulx en Velin, France and operations in the United States, Europe, Asia and other international markets. The firm is listed on the Nasdaq Global Market under the ticker EDAP and has realigned its business to concentrate exclusively on HIFU based applications driven by the Focal One platform.

The company generates revenue from the sale of capital equipment, principally the Focal One Robotic HIFU system, and from recurring revenue streams including consumables, maintenance, and service contracts tied to its installed base. In addition, EDAP TMS S. A. markets and supports legacy extracorporeal shock wave lithotripsy (ESWL) systems, accessories, and related services, and distributes third party urology products such as laser, micro ultrasound, and urodynamics devices. The recurring revenue model provides predictable cash flow as the number of installed systems grows over time.

The company operates through the following segments.

HIFU: This segment develops, manufactures, and sells the Focal One Robotic HIFU system and its consumables, provides maintenance and service support, conducts clinical development for prostate cancer, benign prostatic hyperplasia, and endometriosis indications, and the system features the HIFUsion software for importing MRI, PSMA PET and 3D biopsy maps, a multi axis robotic positioning system with sub millimeter precision, a dynamic focusing probe that combines real time ultrasound imaging with precise HIFU energy delivery, and an integrated cart based workstation designed for ergonomic workflow in the operating room.
ESWL: This segment markets and supports legacy extracorporeal shock wave lithotripsy systems, accessories, and related services, distributes third party urology products including laser, micro ultrasound, and urodynamics devices, contributes to the installed base, generates service revenue, and maintains long standing relationships with urology customers.

EDAP TMS S. A. holds a niche position in the medical device industry as a pioneer of robotic HIFU for focal therapy, competing against established treatment modalities such as radical prostatectomy, radiation therapy, and cryotherapy, as well as other HIFU providers like Sonablate Corporation, Profound Medical Corp., Insightec Ltd., and Haifu. The company’s competitive advantages stem from its proprietary HIFU technology, a growing body of clinical evidence demonstrating noninferior oncologic outcomes and improved functional preservation, regulatory clearances including CE Marking and FDA 510(k) approvals, a robotic platform with AI enabled software potential, and an expanding reimbursement framework in key markets. Additionally, the firm’s intellectual property portfolio includes 71 granted HIFU patents and 15 granted ESWL patents, providing a barrier to entry and supporting long term innovation.

The company serves academic, public, and private hospitals and clinics worldwide, primarily urologists who treat prostate cancer and other urologic conditions, with an increasing focus on gynecologists for the treatment of endometriosis. No single customer represents a significant portion of the installed base, and sales are distributed across multiple geographic regions including North America, Europe, and Asia.

How Edap Tms ranks

Ranked against the 247 companies in Medical Devices and Diagnostics58 metrics · as of Oct 23, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −4.01xMedian 29.7x 34^th
P/FCFNegative free cash flow −11.4xMedian 24.8x 42^nd
P/Operating cash flowNegative operating cash flow −12.0xMedian 20.2x 41^st
P/S 2.26xMedian 3.03x 61^st
P/BNegative shareholder equity −48.3xMedian 2.42x Not meaningful —
P/Tangible bookNegative tangible equity −31.2xMedian 3.04x Not meaningful —
EV/EBITDANegative EBITDA −7.01xMedian 18.0x 27^th
EV/EBITNegative EBIT −6.42xMedian 27.0x 32^nd
EV/Revenue 2.53xMedian 3.09x 59^th
EV/FCFNegative free cash flow −12.8xMedian 26.4x 37^th
EV/Operating cash flowNegative operating cash flow −13.4xMedian 21.5x 34^th
PEG (3Y EPS CAGR)Negative earnings 0.16Median 0.97 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 15.4%Median 9.0% 62^nd
Revenue CAGR (3Y) 4.8%Median 8.4% 41^st
Gross profit growth (1Y) 21.1%Median 12.5% 66^th
Gross profit CAGR (3Y) 8.1%Median 8.7% 48^th
Operating income growth (1Y) −16.3%Median 9.1% 31^st
Operating income CAGR (3Y) −20.7%Median 8.1% 17^th
Net income growth (1Y) −68.2%Median 8.7% 14^th
Net income CAGR (3Y) −28.0%Median 9.3% 15^th
EPS growth (1Y) −68.8%Median 27.7% 13^th
EPS CAGR (3Y) −24.5%Median 21.0% 15^th
Operating cash flow growth (1Y) 7.6%Median 5.7% 53^rd
Operating cash flow CAGR (3Y) 8.1%Median 11.3% 41^st
Free cash flow growth (1Y) 3.7%Median 4.5% 49^th
Free cash flow CAGR (3Y) 6.7%Median 14.4% 37^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 46.0%Median 58.4% 26^th
EBITDA margin −36.0%Median −4.3% 36^th
Operating margin −39.3%Median −11.1% 38^th
Pretax margin −55.7%Median −13.5% 35^th
Net margin −56.4%Median −15.0% 33^rd
FCF margin −19.8%Median −2.7% 38^th
Operating cash flow margin −18.9%Median −0.5% 37^th
Return on equityNegative shareholder equity −1,145%Median −23.9% Not meaningful —
Return on assets −53.7%Median −17.6% 31^st
Return on invested capital −76.3%Median 0.9% 11^th
Return on capital employed −74.4%Median −16.8% 25^th
Asset turnover 0.94xMedian 0.57x 79^th
Cash conversion (OCF / net income)Net income is not positive 0.34xMedian 1.51x Not meaningful —
Stock comp / revenue 2.9%Median 5.9% 68^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 53.5%Median 29.9% 19^th
Debt / equityNegative shareholder equity −12.4xMedian 0.47x Not meaningful —
Net debt / EBITDAEBITDA is not positive −0.74xMedian 2.12x Not meaningful —
Debt / FCFFree cash flow is not positive −2.93xMedian 4.03x Not meaningful —
Liabilities / assets 104%Median 45.5% 13^th
Equity / assetsNegative shareholder equity −4.3%Median 54.5% 13^th
Interest coverage —Median −2.13x No data —
Current ratio 1.60xMedian 2.99x 22^nd
Quick ratio 0.90xMedian 1.83x 23^rd
Cash ratio 0.58xMedian 1.15x 29^th
Altman Z-score −1.58Median 1.47 36^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	250.06 Bn	36.01	5.40	42.55 Bn
2	ABT	Abbott Laboratories	177.62 Bn	32.93	3.81	32.61 Bn
3	DHR	Danaher Corp /De/	161.58 Bn	40.49	6.44	26.56 Bn
4	ISRG	Intuitive Surgical Inc	153.84 Bn	52.38	13.29	-
5	MDT	Medtronic plc	123.63 Bn	23.63	3.29	28.15 Bn
6	SYK	Stryker Corp	117.79 Bn	31.58	4.56	14.94 Bn
7	BSX	Boston Scientific Corp	66.71 Bn	18.41	3.18	12.62 Bn
8	FOCL	Edap Tms Sa	0.16 Bn	-4.01	2.26	0.04 Bn

Edap Tms FOCL

About

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

How Edap Tms ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Edap Tms FOCL

About

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

How Edap Tms ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password